-
公开(公告)号:TW200540155A
公开(公告)日:2005-12-16
申请号:TW094113637
申请日:2005-04-28
Inventor: 野正博 KAJINO, MASAHIRO , 哈特尼可拉斯威廉 HIRD, NICHOLAS WILLIAM , 樽井直樹 TARUI, NAOKI , 野浩 BANNO, HIROSHI , 川野泰彥 KAWANO, YASUHIKO , 稻富信博 INATOMI, NOBUHIRO
CPC classification number: C07D471/04
Abstract: 本發明提供一種具有神經激2(neurokinin 2;NK2)受體拮抗作用之衍生物,其係由式(I)代表之化合物或其鹽等等094113637-p01.bmp其中R^1為氫原子等等,R^2為氫原子、烴基(其可視需要具有取代基)等等;R^3為未取代(亦即不存在)、氫原子等等;R^4與R^5相同或相異,分別為氫原子、烴基(其可視需要具有取代基)等等;R^6為(環狀基團,其可視需要具有取代基)–羰基等等;R^7、R^8、R^9與R^10相同或相異,分別為氫原子、鹵素等等;或R^7與R^8、R^8與R^9、及R^9與R^10可與相鄰碳原子共同形成環;n為整數1至5;–––代表未取代(亦即不存在)或單鍵;及 代表單鍵或雙鍵。094113637-p01.bmp
Abstract in simplified Chinese: 本发明提供一种具有神经激2(neurokinin 2;NK2)受体拮抗作用之衍生物,其系由式(I)代表之化合物或其盐等等094113637-p01.bmp其中R^1为氢原子等等,R^2为氢原子、烃基(其可视需要具有取代基)等等;R^3为未取代(亦即不存在)、氢原子等等;R^4与R^5相同或相异,分别为氢原子、烃基(其可视需要具有取代基)等等;R^6为(环状基团,其可视需要具有取代基)–羰基等等;R^7、R^8、R^9与R^10相同或相异,分别为氢原子、卤素等等;或R^7与R^8、R^8与R^9、及R^9与R^10可与相邻碳原子共同形成环;n为整数1至5;–––代表未取代(亦即不存在)或单键;及 代表单键或双键。094113637-p01.bmp
-
272.
公开(公告)号:TW200529890A
公开(公告)日:2005-09-16
申请号:TW094103569
申请日:2005-02-04
Inventor: 齋藤和宏 SAITO, KAZUHIRO , 布藤智康 FUTO, TOMOMICHI , 星野哲夫 HOSHINO, TETSUO
CPC classification number: A61K9/5031 , A61K9/5089 , A61K38/08 , A61K38/24 , A61K47/34
Abstract: 一種持續釋放製劑包含長時間徐緩釋放GnRH促效劑或其鹽之微囊,與短時間徐緩釋放GnRH促效劑或其鹽之微囊之組合。094103569-p01.bmp
Abstract in simplified Chinese: 一种持续释放制剂包含长时间徐缓释放GnRH促效剂或其盐之微囊,与短时间徐缓释放GnRH促效剂或其盐之微囊之组合。094103569-p01.bmp
-
公开(公告)号:GEP20197050B
公开(公告)日:2019-12-10
申请号:GEAP2015014545
申请日:2015-12-17
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: TAKEDA PHARMACEUTICAL COMPANY LIMITED
IPC: C07D471/04
Abstract: An invention relates to crystalline form of 6-(lR,2S)-2-aminocyclohexylamino)-7-fluoro-4-(1-me-thyl-1H-pyrazol-4-yl)-lH-pyrrolo[3,4-c]pyridine-3 (2H)-one citrate, which is inhibitor of spleen tyrosine kinase (SYK); and usage of this compound for cancer treatment, as well.
-
公开(公告)号:GEP20196970B
公开(公告)日:2019-04-25
申请号:GEAP2015014277
申请日:2015-02-23
Applicant: TAKEDA GMBH , TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: TAKEDA GMBH , TAKEDA PHARMACEUTICAL COMPANY LIMITED
Abstract: Present invention provides UTI fusion proteins, DNA sequences for producing thereof, and pharma¬ceutical compositions and methods of their usage.
-
公开(公告)号:GEP20196961B
公开(公告)日:2019-03-25
申请号:GEAP2015014515
申请日:2015-11-19
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: TAKEDA PHARMACEUTICAL COMPANY LIMITED
IPC: C07D253/08 , A61K31/53
Abstract: An invention relates to oxobenzo [d] [1,2,3] triazine acetamides of formula (II), containing pharmaceutical compositions thereof, and their usage for the treatment of diseases related to GPR139.
-
公开(公告)号:GEP20196984B
公开(公告)日:2019-06-25
申请号:GEAP2015014284
申请日:2015-03-06
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: TAKEDA PHARMACEUTICAL COMPANY LIMITED
IPC: A61K31/501 , A61P25/14 , A61P25/00
Abstract: An invention relates to hydroxypyridazine derivatives of formula (I), (I) pharmaceutically acceptable salts thereof, their usage for the prevention or treatment of an ataxic disorder.
-
公开(公告)号:GEP20186910B
公开(公告)日:2018-10-25
申请号:GEAP2015014273
申请日:2015-02-19
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: TAKEDA PHARMACEUTICAL COMPANY LIMITED
IPC: A61P25/18 , A61K31/44 , A61K31/506 , C07D213/74 , C07D231/12 , C07D239/42 , C07D249/06 , C07D271/07
Abstract: Compound of formula (I), (I) wherein values of R1, R2, R3, Ra, Rb, L, X substitudes are provided in the claims or pharmaceutically acceptable salt thereof, pharmaceutical compositions containing them, and their usage at the therapy. Table: 1
-
公开(公告)号:MA39193B1
公开(公告)日:2018-04-30
申请号:MA39193
申请日:2014-12-19
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: HITCHCOCK STEPHEN , MONENSCHEIN HOLGER , REICHARD HOLLY , KIKUCHI SHOTA , MACKLIN TODD , HOPKINS MARIA , BROWN JASON , SCHLEICHER KRISTIN , SUN HUKAI
IPC: A61K31/4985 , A61P25/16 , C07D471/04
Abstract: La présente invention concerne des composés de formule (i) : qui sont utiles comme modulateurs du gpr6, des compositions pharmaceutiques les contenant, des procédés de traitement de maladies associées au gpr6, et des procédé de fabrication des composés et de leurs intermédiaires.
-
公开(公告)号:MA38391A1
公开(公告)日:2018-01-31
申请号:MA38391
申请日:2014-03-10
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: LAWSON JOHN DAVID , SABAT MARK , SCORAH NICHOLAS , SMITH CHRISTOPHER , VU PHONG H , WANG HAIXIA
IPC: A61K31/4725 , A61P35/00 , C07D401/04 , C07D401/14 , C07D403/14
Abstract: L'invention concerne des composés de formule 1 ou des sels pharmaceutiquement acceptables de ceux-ci, dans la formule, r1, r2, r3, et r4 sont tels que définis dans la description. Cette invention concerne également des matières et des procédés permettant de préparer les composés de formule 1, des compositions pharmaceutiques contenant ces composés, ainsi que leur utilisation pour traiter des réactions d'hypersensibilité de type i, des maladies auto-immunes, des troubles inflammatoires, le cancer, des troubles proliférants bénins, et d'autres états associés à la tyrosine kinase de bruton (btk).
-
280.
公开(公告)号:GEP20186909B
公开(公告)日:2018-10-25
申请号:GEAP2015014272
申请日:2015-02-19
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: TAKEDA PHARMACEUTICAL COMPANY LIMITED
IPC: A61P25/18 , A61K31/428 , C07D263/58 , C07D277/82 , C07D401/04
Abstract: Compound of formula (I), (I) wherein values of R1, R2, R3, Ra, Rb, L, X substitudes are provided in the claims or pharmaceutically acceptable salt thereof, pharma¬ceutical compositions containing them, and their usage at the therapy. Table: 1
-
-
-
-
-
-
-
-
-